Phase 1Completed

Bioequivalence Study Between Temozolomide Oral Suspension (Ped-TMZ) and Temodal® Capsules

Sponsor
Orphelia Pharma (Industry)
Enrollment
36 enrolled
Conditions
Therapeutic Equivalency
Interventions
Ped-TMZ
Ages
adults, older adults
Registry
NCT04467346

Full record on ClinicalTrials.gov

From the registry

Primary objective: • Evaluate bioequivalence between Temozolomide Oral Suspension and Temodal® capsules for oral administration. Secondary objectives: * Define the pharmacokinetic parameters of Temozolomide Oral Suspension. * Assess the buccal safety of Temozolomide Oral Suspension.

Primary outcomes

  • Primary pharmacokinetic parameter: Cmax
  • Primary pharmacokinetic parameter: AUC0-t

History

  1. Last registry update

  2. Primary completion

  3. Started

  4. Registered